#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Asthma Sarcoidosis Acquired haemophilia Chronic graft versus host disease in liver Myotonia Cutaneous lupus erythematosus Von Hippel-Lindau disease NTRK gene fusion overexpression Congenital absence of bile ducts Paraneoplastic neurological syndrome B-cell small lymphocytic lymphoma Stress cardiomyopathy Pulmonary sarcoidosis Ewing's sarcoma recurrent Crigler-Najjar syndrome More trials…

    Learn about Rare Diseases

    Hereditary angioedema with C1 esterase inhibitor deficiency Alagille syndrome Synovial sarcoma – Basic Information Haemophagocytic lymphohistiocytosis – Diagnostics Familial haemophagocytic lymphohistiocytosis – Life with Disease Osteosarcoma metastatic – Basic Information Prader-Willi syndrome – Life with Disease Mantle cell lymphoma stage II – Trials in Disease Systemic mastocytosis – Treatment Sarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Human Coagulation Factor X Azd0305 Prednisolone Bintrafusp Alfa Tolvaptan Amlodipine Viltolarsen Azd8421 Dersimelagon Phosphate Dinutuximab Beta Venglustat MB-HUCART19.1 Hepatitis B Surface Antigen Mps-106 Insulin Aspart Levamlodipine Succinate GSK5784283 PEGVISOMANT Mitapivat LYSERGIDE More therapies…

    Learn about Your Condition

    Mantle cell lymphoma stage III Adenosquamous cell lung cancer Rectal cancer recurrent Dupuytren's contracture Porphyria non-acute Anal cancer Oral neoplasm Insulin resistance Mucous membrane pemphigoid Autoimmune disorder Peritoneal sarcoma Fabry's disease Substance use disorder Pouchitis Noonan syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliera di Padova

Azienda Ospedaliera di Padova

Via Nicolo' Giustiniani 2, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

    Recruiting

    3 1 1
    Investigated Diseases:
    • Graves’ disease
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

    Recruiting

    2 1
    Czechia Italy Poland

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Haemophilia B without inhibitors
    • Haemophilia A without inhibitors
    • Factor IX deficiency
    Investigated Drugs:
    • Concizumab
    Bulgaria France Greece Italy Lithuania Norway +4

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Tirzepatide
    • Mirikizumab
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    Denmark Finland France Italy The Netherlands Poland +2

  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

    Recruiting

    3 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • 2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
    • Ruxolitinib
    Austria Belgium Czechia France Germany Italy +3

  • Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

    Recruiting

    2 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Ro7790121
    Belgium Denmark France Germany Italy Poland +1
1 2 3 … 41
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!